The National MS Society has awarded $4.6 million in funding for five research projects aiming to help restore lost function ...

Sanofi stopped a Phase 2 study of oditrasertib in relapsing and progressive MS after it failed to lower blood NfL levels ...

Curiously, columnist Leigh Anne Nelson can't tolerate wearing socks. It's one of several foot symptoms of her MS.

People with MS may have a slightly higher risk of developing cancer than the general population, per a 10-year population ...

A study involving identical twins suggests alterations in immune cells called CD8 T-cells may be early drivers of ...

Adding Tecfidera to an immune tolerizing cell therapy could maximize therapeutic benefits for MS patients, according to a ...

SetPoint plans to launch a trial of its implant device, stimulating the vagus nerve to promote myelin repair, next year in ...

Plasma exchange therapy is effective for severe relapses in MS patients who respond inadequately to standard corticosteroids, ...

The Foundation of the Consortium of Multiple Sclerosis Centers was gifted $100,000 by EMD Serono for its nursing scholarship ...

Better adherence to an at-home therapy regimen with the PoNS device was linked to greater improvements in walking function in ...

Faced with the loss of cognitive abilities from multiple sclerosis, columnist Ben Hofmeister grapples with a bout of depression.

A sublingual formulation of cladribine showed comparable pharmacological properties to its name brand counterpart, Mavenclad.